Golimumab vs placebo for stage 1 diabetes prevention
Treatments studied
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests whether the drug golimumab (an immune-modulating medicine) can delay or prevent type 1 diabetes in people who have early signs of autoimmunity but still have normal blood sugar. It compares golimumab to a placebo (a dummy treatment) to see if it can protect the insulin-making cells in the pancreas.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 2 and 44 years old and weigh at least 33 pounds (15 kg).
- You must have had a blood test showing at least two diabetes-related autoantibodies (or just one called IA-2A) on more than one occasion in the last 6 months.
- Your blood sugar levels must be normal (tested with a glucose drink test within the last 7 weeks).
- You cannot have active infections, a history of tuberculosis, or have had a live vaccine in the last 4 weeks.
- You cannot be pregnant, breastfeeding, or planning to become pregnant during the study.
- You must not have other autoimmune diseases (except stable thyroid or celiac disease) or be on medications that affect blood sugar.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an immune-suppressing medicine (anti-thymocyte globulin) in people with type 1 diabetes to see if it can help save the body's ability to make insulin. It is for people aged 5–40 who were diagnosed recently or have had diabetes for up to 2 years.
This trial compares two medicines, teplizumab and ATG, to see if they can delay or prevent type 1 diabetes from progressing to needing insulin. It is for people ages 4 to 35 who have early signs of diabetes (stage 2) and specific autoantibodies.
This study tests two different medications (Anti-Thymocyte Globulin and Adalimumab or Verapamil) to see if they can slow down the loss of insulin production in people with newly diagnosed type 1 diabetes. Participants will be randomly assigned to receive one of the treatments and will be followed for about a year to see how well their bodies still make insulin.
This trial tests a new way to give a medicine called anti-thymocyte globulin (ATG) with or without verapamil, a blood pressure drug. It aims to slow down the loss of insulin-making cells in people newly diagnosed with type 1 diabetes.
This trial tests a new combination treatment for children who have been diagnosed with stage 1 type 1 diabetes, meaning they have some markers but do not yet need insulin. The treatment uses special immune cells (Treg cells) and an antibody (anti-CD20) to try to preserve the body's ability to make insulin.
This early-stage trial tests a combination approach to help your immune system stop attacking insulin-producing cells in newly diagnosed type 1 diabetes. It aims to preserve your body's ability to make insulin and slow disease progression.
Hear when a new Type 1 Diabetes (T1D) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.